Adithya K. Yadalam, MD, MSc

Emory Cardiology Fellow. Enthusiast of all things Western classical music, literary realism, and cardio-oncology.

[Adithya K. Yadalam, MD, MSc @akyadalam]

Honored and excited to be invited to the Heart In Diabetes 2026 conference to share insights on how a proteomics-based risk score can meaningfully improve risk prediction for incident CKM disease among healthy individuals.

Full paper here: https://t.co/eQmduH486M

[Yehuda Handelsman MD FACP, FNLA, FASPC, FAHA, MACE @YHandelsmanMD]

Introducing the Joint Session, "Circulation" with our renowned speakers at the 10th Heart in Diabetes, and don't miss out on earning #CME credits!

Register now at https://t.co/j4IkqQ2Ly9

#10HID #HID2026 #MedEd #MedicalConference

[Adithya K. Yadalam, MD, MSc @akyadalam]

Had a great time presenting our work on the impact of suPAR on adverse CV outcomes in female survivors of breast cancer as a finalist for the 2nd annual MGB–Inova Young Investigator Award in Women’s Cardiovascular Health – an immensely important and consequential field of study.

[Adithya K. Yadalam, MD, MSc @akyadalam]

Honored to be selected as a finalist for this young investigator award in women’s cardiovascular health!

[Mass General Brigham Women's Heart Health Program @MGBWomenHeart]

Our team is thrilled to head to VA to judge an incredible group of finalists for the 2nd MGB Inova YIA in Women’s Cardiovascular Health. Congrats to all the finalists!🥳 @GarimaVSharmaMD @NanditaScottMD
@ISHVnews @MassGeneralNews

[Adithya K. Yadalam, MD, MSc @akyadalam]

@salimhayek @the_asci @utmbhealth @umichCVC Congrats, Salim!

[Adithya K. Yadalam, MD, MSc @akyadalam]

@preetsingh6s In our cohort of 90 men with prostate cancer (mean age 67.5; SD 8.1), the prevalence of clonal hematopoiesis was 20%.

[Adithya K. Yadalam, MD, MSc @akyadalam]

Presenting our work on the intersection of clonal hematopoiesis, androgen deprivation therapy, and longitudinal coronary plaque change in men with prostate cancer – with much more to come. #ACC2026

[Adithya K. Yadalam, MD, MSc @akyadalam]

And as always, grateful for the continued mentorship of @CardioOnc_ATL and @sagarapatel.

[Adithya K. Yadalam, MD, MSc @akyadalam]

Working with lead trialists @sagarapatel and @CardioOnc_ATL on the REVELUTION RCT has been such an incredibly enriching experience. Much more to come in the world of prostate cancer therapeutics and CVD.

[Adithya K. Yadalam, MD, MSc @akyadalam]

Now in @JAMACardio – the REVELUTION RCT. In this RCT of men with localized prostate cancer, we show that randomization to GnRH-agonist ADT was significantly associated with an increase in 12-month coronary artery plaque compared to GnRH-antagonist ADT.

https://t.co/PrtK41wRbt

[JAMA Cardiology @JAMACardio]

Among men with localized #ProstateCancer, treatment with GnRH agonist leuprolide resulted in greater 12-month coronary plaque progression vs GnRH antagonist relugolix, driven by increased noncalcified plaque volume.

https://t.co/CrB83NYzyy

[Adithya K. Yadalam, MD, MSc @akyadalam]

@JochenReiser Love all things Ishiguro – would also strongly recommend The Remains of the Day. Same emotional restraint, but instead about duty: both its dignity and its cost.

[Adithya K. Yadalam, MD, MSc @akyadalam]

@AGangavelli @AlexRazavi @EmoryCCRI @emory_heart

[Adithya K. Yadalam, MD, MSc @akyadalam]

Very nice editorial of our recent publication in @JCardFail describing the association of lipoprotein(a) with CV outcomes in patients with HF – appreciate the authors’ efforts and commentary on further contextualizing our findings to a clinical context.

https://t.co/UgLGkJbOaD

[Adithya K. Yadalam, MD, MSc @akyadalam]

@StefanoByer @JACCJournals @ICOSociety @UIowaCVFellows Big congrats, Stefano! Looking forward to reading it.

[Adithya K. Yadalam, MD, MSc @akyadalam]

Excited to share the final version of our manuscript in @Circ_Gen detailing our novel, large-scale proteomics risk score, which significantly improved risk prediction for incident cardio-kidney-metabolic disease in over >23,000 UK Biobank participants.

https://t.co/eQmduH4FWk

[Adithya K. Yadalam, MD, MSc @akyadalam]

In all, we show that the ProtRS significantly:
⭐️ Predicted incident CKM-D outcomes independent of trad'l RFs
⭐️ Enhanced incident CKM-D outcome risk discrimination beyond trad'l RFs
⭐️ Improved incident 10-year CVD risk prediction beyond participants' PREVENT scores

🧵 [8/X]

[Adithya K. Yadalam, MD, MSc @akyadalam]

Now published in @Circ_Gen:
🧍 In 23,815 UK Biobank participants free of cardio-kidney-metabolic disease (CKM-D)
🧬 A large-scale proteomics risk score
⭐️ Significantly improved risk prediction for incident CKM-D beyond trad'l risk factors (RFs)
🧵 [1/X]

https://t.co/UAkFgFZopJ

[Adithya K. Yadalam, MD, MSc @akyadalam]

Moreover, the addition of the ProtRS to participants' PREVENT scores significantly improved 10-year incident CVD risk discrimination (C-index, 0.757 [95% CI, 0.730–0.784]; ΔC-index, 0.049 [95% CI, 0.028–0.071] beyond the PREVENT score alone

🧵 [7/X]